Samsara Biocapital, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Samsara Biocapital, LLC reported 24 stock positions worth $1.2 billion. Its top holding was Scholar Rock (SRRK) at 31.2% of the portfolio, followed by Alumis (ALMS, 14.7%) and Mineralys Therapeutics (MLYS, 13.0%). Compared with Q1 2026, it opened 4 new positions, sold out of 2, added to 2 and reduced 5. The biggest buy was a new position in Alamar Biosciences (ALMR) and the biggest sale Kalaris Therapeutics (KLRS, shares −1%).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001744967
- Portfolio Value
- $1.2B (Q2 2026)
- SEC Filing
- 0001744967-26-000010 ↗ filed Aug 14, 2026
Holdings Value
Holdings 24 stocks · $1.2B
| SRRK Scholar Rock Holding Corp. | 31.16% | 6,897,652 | $379.4M | No change |
| ALMS Alumis Inc. | 14.67% | 6,345,219 | $178.6M | No change |
| MLYS Mineralys Therapeutics Inc. | 13.01% | 5,871,018 | $158.4M | No change |
| SEPN Septerna Inc. | 8.66% | 3,149,128 | $105.5M | No change |
| ALMR Alamar Biosciences Inc. | 5.52% | 2,480,310 | $67.2M | New |
| NGNE Neurogene Inc. | 4.44% | 1,717,127 | $54.0M | No change |
| KLRS Kalaris Therapeutics Inc. | 4.31% | 12,881,175 | $52.4M | Reduce -0.5% |
| SGP Spyglass Pharma Inc. | 3.86% | 2,109,953 | $47.0M | No change |
| STRO Sutro Biopharma Inc. | 2.90% | 1,062,872 | $35.3M | No change |
| IVA Inventiva SA - ADR | 1.96% | 6,314,805 | $23.9M | Add +21.6% |
| JBIO Jade Biosciences Inc. | 1.34% | 736,237 | $16.4M | Reduce -24.0% |
| PBLS Parabilis Medicines Inc. | 1.25% | 556,044 | $15.2M | New |
| VTVT VTV Therapeutics Inc. Class A | 0.92% | 298,496 | $11.2M | No change |
| AQST Aquestive Therapeutics Inc. | 0.85% | 2,500,000 | $10.4M | No change |
| NKTX Nkarta Inc. | 0.82% | 3,507,666 | $9.9M | No change |
| ARTV Artiva Biotherapeutics Inc. | 0.76% | 954,861 | $9.3M | New |
| RANI Rani Therapeutics Holdings Class A | 0.65% | 10,369,159 | $7.9M | Add +22.0% |
| AGMB Agomab Therapeutics NV | 0.64% | 600,000 | $7.8M | No change |
| ABVX Abivax SA-ADR | 0.60% | 55,095 | $7.3M | Reduce -2.6% |
| XFOR X4 Pharmaceuticals Inc. | 0.54% | 1,395,587 | $6.5M | Reduce -23.9% |
| ELOX Eloxx Pharmaceuticals Inc. | 0.46% | 400,000 | $5.6M | New |
| CHRS Coherus Oncology Inc. | 0.39% | 3,428,571 | $4.8M | No change |
| UPB Upstream Bio Inc. | 0.20% | 353,717 | $2.4M | Reduce -51.9% |
| GOSS Gossamer Bio Inc. | 0.10% | 7,222,559 | $1.2M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| KLRS Kalaris Therapeutics Inc. | Reduce -0.5% | 4.31% | −2.95 |
| ACLX Arcellx Inc. | Sold out | 0.00% | −0.68 |
| PVLA Palvella Therapeutics Inc. | Sold out | 0.00% | −0.47 |
| UPB Upstream Bio Inc. | Reduce -51.9% | 0.20% | −0.44 |
| XFOR X4 Pharmaceuticals Inc. | Reduce -23.9% | 0.54% | −0.20 |
| ABVX Abivax SA-ADR | Reduce -2.6% | 0.60% | −0.01 |
| JBIO Jade Biosciences Inc. | Reduce -24.0% | 1.34% | +0.02 |
Portfolio Buys Q1 2026 → Q2 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 24 | $1.2B | SRRK, ALMS, MLYS, SEPN, ALMR |
| Q1 2026 | 22 | $1.0B | SRRK, MLYS, ALMS, SEPN, KLRS |
| Q4 2025 | 20 | $969.2M | SRRK, MLYS, KLRS, SEPN, ALMS |
| Q3 2025 | 25 | $765.9M | MLYS, SRRK, KLRS, SEPN, NGNE |
| Q2 2025 | 27 | $488.9M | SRRK, MLYS, SEPN, KLRS, NGNE |
| Q1 2025 | 35 | $560.8M | SRRK, KLRS, MLYS, NGNE, ALMS |
| Q4 2024 | 41 | $728.6M | SRRK, CRGX, SEPN, MLYS, NGNE |
| Q3 2024 | 40 | $520.3M | CRGX, MLYS, SRRK, NGNE, ALMS |
| Q2 2024 | 38 | $477.8M | CRGX, MLYS, SRRK, NGNE, ACLX |
| Q1 2024 | 37 | $646.3M | SRRK, CRGX, MLYS, NGNE, NKTX |